ACB
Aurora Cannabis Inc.
ACB lost money over the past year, so it has no meaningful PE right now.
ACB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ACB's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
ACB PE Valuation
ACB has no meaningful PE right now: it lost money over the past year.
ACB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect ACB's profitability to weaken, with its earnings and revenue holding steady.
ACB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.36 | -500% |
| Q1 2026 | -$0.91 | -2375% |
| Q4 2025 | -$0.53 | -431% |
| Q3 2025 | -$0.14 | +$0.47 |
| Q2 2025 | $0.34 | +$0.80 |
| Q1 2025 | $0.04 | +$1.18 |
| Q4 2024 | $0.16 | +$2.37 |
| Q3 2024 | -$0.61 | +$2.63 |
ACB has swung to a loss: it lost $1.36 per share over the past year, after a profit the year before.
ACB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $47.5M | -23% |
| Q1 2026 | $26.8M | -58% |
| Q4 2025 | $66.2M | +6.8% |
| Q3 2025 | $63.5M | +11% |
| Q2 2025 | $62M | +5.7% |
| Q1 2025 | $63.7M | +34% |
| Q4 2024 | $62M | +37% |
| Q3 2024 | $57M | +29% |
ACB's revenue is shrinking: $48M last quarter, down 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -70% | -112 points |
| Q1 2026 | -66% | -33 points |
| Q4 2025 | 5.1% | -37 points |
| Q3 2025 | -20% | -17 points |
| Q2 2025 | 42% | +41 points |
| Q1 2025 | -34% | -38 points |
| Q4 2024 | 42% | +69 points |
| Q3 2024 | -3% | +14 points |
ACB's operating margin was −70% last quarter, down 112 points from the same quarter a year ago.
ACB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -294% |
| Q1 2026 | -$3.8M | -$3.4M |
| Q4 2025 | $7.7M | -54% |
| Q3 2025 | -$32.9M | -$12.2M |
| Q2 2025 | $3.6M | +58% |
| Q1 2025 | -$438K | +$18.4M |
| Q4 2024 | $16.9M | +$22.5M |
| Q3 2024 | -$20.7M | +$4M |
ACB has burned cash in most quarters: −$36M over the past year, against −$702,335 the year before.
ACB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.3% | +4.2M shares |
| 1 year | +11% | +5.9M shares |
| 3 years | +74% | +26.3M shares |
| 5 years | +212% | +41.9M shares |
| Available history | +612% | +53M shares |
ACB has 62M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ACB hasn't bought back shares in the past year.
ACB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.6x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -4.5x | Net Cash |
| Q2 2024 | -5.2x | Net Cash |
| Q4 2023 | -0.2x | Net Cash |
ACB has more cash than debt.
ACB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.6 | Neutral |
| Stochastic | 84.8 | Overbought |
ACB's weekly RSI is 65 (neutral) and its Stochastic is 85 (overbought).
ACB PE vs Healthcare Sector
| Metric | ACB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACB has no meaningful PE right now: it lost money over the past year.
ACB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.33 | 15% above |
| 20 week MA | $3.72 | 34% above |
| 50 week MA | $3.73 | 34% above |
| 100 week MA | $4.26 | 17% above |
| 200 week MA | $5.00 | 0.2% below |
ACB has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.2% below its 200-week average.
ACB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $229.2 | $88.7 | -61% |
| 2021 | $88.7 | $61.2 | -31% |
| 2022 | $61.2 | $9.27 | -85% |
| 2023 | $9.27 | $4.76 | -49% |
| 2024 | $4.76 | $4.30 | -9.7% |
| 2025 | $4.30 | $4.49 | +4.4% |
| 2026 YTD | $4.49 | $4.99 | +11% |
ACB has finished lower in five of the last six years. It's up 11% so far in 2026.